New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China.
Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...
Trump’s executive orders included overhauls to U.S. trade policy and declaring a national emergency at the southern border.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cance ...
The U.S. Food and Drug Administration (FDA) has declared an end to shortages of the GLP-1 drugs Mounjaro and Zepbound, a move that means online pharmacies will have to stop selling compounded ...
Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...
To corral costs, Keith is leading a new initiative at BCBSM called Blue Cross Accelerated that aims to cut $600 million in ...
DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...
Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...